Search research articles
Contact Us
Filters
Showing results (41-50 of 56) with videos related to
Page
of 6
Sort By:
Journal of Clinical Pharmacology
|
February 7, 2020
Population Pharmacokinetics and Exposure-Response Modeling Analyses of Ustekinumab in Adults With Moderately to Severely Active Ulcerative Colitis
Yan Xu, Chuanpu Hu, Yang Chen, et al.
The AAPS Journal
|
August 4, 2020
Application of Trial Simulation in the Design of a Prospective Study for Concentration-QTc Analysis in Support of a Thorough QT Study Waiver
Peijuan Zhu, Chyi-Hung Hsu, Chuanpu Hu, et al.
Journal of Clinical Pharmacology
|
January 18, 2018
Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1λ Monoclonal Antibody Targeting IL-23, in Patients with Moderate to Severe Plaque Psoriasis
Zhenling Yao, Chuanpu Hu, Yaowei Zhu, et al.
Journal of Clinical Pharmacology
|
January 31, 2009
Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis
Yaowei Zhu, Chuanpu Hu, Ming Lu, et al.
European Journal of Clinical Pharmacology
|
September 17, 2009
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Adedigbo A Fasanmade, Omoniyi J Adedokun, Joyce Ford, et al.
Journal of Clinical Pharmacology
|
November 26, 2013
Utility of population pharmacokinetic modeling in the assessment of therapeutic protein-drug interactions
Andrew T Chow, Justin C Earp, Manish Gupta, et al.
Journal of Clinical Pharmacology
|
December 12, 2018
Population Pharmacokinetics and Exposure-Response Modeling Analyses of Golimumab in Children With Moderately to Severely Active Ulcerative Colitis
Yan Xu, Omoniyi J Adedokun, Daphne Chan, et al.
Clinical Therapeutics
|
February 20, 2022
Population Pharmacokinetic and Exposure-Response Model Simulations: Predicted Exposure and Efficacy for Maintenance Doses of Intravenous Golimumab Every 6 or 8 Weeks in Patients With Moderately to Severely Active Rheumatoid Arthritis
Jong Bong Lee, Aaron Broadwell, Yijun Fan, et al.
Journal of Clinical Pharmacology
|
May 18, 2017
The Utility of a Population Approach in Drug-Drug Interaction Assessments: A Simulation Evaluation
Diane D Wang, Yanke Yu, Nastya Kassir, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
November 11, 2025
Integrating MBMA and QSP to Identify Key Covariates and Predict Treatment Outcomes in Relapsed/Refractory Multiple Myeloma
Zeel Shah, Clifton M Anderson, Kevin D McCormick, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 56) with videos related to
Sort By:
Page
of 6
Journal of Clinical Pharmacology
|
February 7, 2020
Population Pharmacokinetics and Exposure-Response Modeling Analyses of Ustekinumab in Adults With Moderately to Severely Active Ulcerative Colitis
Yan Xu, Chuanpu Hu, Yang Chen, et al.
The AAPS Journal
|
August 4, 2020
Application of Trial Simulation in the Design of a Prospective Study for Concentration-QTc Analysis in Support of a Thorough QT Study Waiver
Peijuan Zhu, Chyi-Hung Hsu, Chuanpu Hu, et al.
Journal of Clinical Pharmacology
|
January 18, 2018
Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1λ Monoclonal Antibody Targeting IL-23, in Patients with Moderate to Severe Plaque Psoriasis
Zhenling Yao, Chuanpu Hu, Yaowei Zhu, et al.
Journal of Clinical Pharmacology
|
January 31, 2009
Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis
Yaowei Zhu, Chuanpu Hu, Ming Lu, et al.
European Journal of Clinical Pharmacology
|
September 17, 2009
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Adedigbo A Fasanmade, Omoniyi J Adedokun, Joyce Ford, et al.
Journal of Clinical Pharmacology
|
November 26, 2013
Utility of population pharmacokinetic modeling in the assessment of therapeutic protein-drug interactions
Andrew T Chow, Justin C Earp, Manish Gupta, et al.
Journal of Clinical Pharmacology
|
December 12, 2018
Population Pharmacokinetics and Exposure-Response Modeling Analyses of Golimumab in Children With Moderately to Severely Active Ulcerative Colitis
Yan Xu, Omoniyi J Adedokun, Daphne Chan, et al.
Clinical Therapeutics
|
February 20, 2022
Population Pharmacokinetic and Exposure-Response Model Simulations: Predicted Exposure and Efficacy for Maintenance Doses of Intravenous Golimumab Every 6 or 8 Weeks in Patients With Moderately to Severely Active Rheumatoid Arthritis
Jong Bong Lee, Aaron Broadwell, Yijun Fan, et al.
Journal of Clinical Pharmacology
|
May 18, 2017
The Utility of a Population Approach in Drug-Drug Interaction Assessments: A Simulation Evaluation
Diane D Wang, Yanke Yu, Nastya Kassir, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
November 11, 2025
Integrating MBMA and QSP to Identify Key Covariates and Predict Treatment Outcomes in Relapsed/Refractory Multiple Myeloma
Zeel Shah, Clifton M Anderson, Kevin D McCormick, et al.
Page
of 6